نتایج جستجو برای: fulvestrant

تعداد نتایج: 782  

2014
Shuying Liu Xiaolong Meng Huiqin Chen Wenbin Liu Todd Miller Mandi Murph Yiling Lu Fan Zhang Mihai Gagea Carlos L. Arteaga Gordon B. Mills Funda Meric-Bernstam Ana M. González-Angulo

Despite numerous therapies that effectively inhibit estrogen signaling in breast cancer, a significant proportion of patients with estrogen receptor (ER)-positive malignancy will succumb to their disease. Herein we demonstrate that long-term estrogen deprivation (LTED) therapy among ER-positive breast cancer cells results in the adaptive increase in ER expression and subsequent activation of mu...

2008
Xinghua Long Meiyun Fan Robert M. Bigsby Kenneth P. Nephew

Breast cancer resistance to the antiestrogens tamoxifen (OHT) and fulvestrant is accompanied by alterations in both estrogen-dependent and estrogen-independent signaling pathways. Consequently, effective inhibition of both pathways may be necessary to block proliferation of antiestrogen-resistant breast cancer cells. In this study, we examined the effects of apigenin, a dietary plant flavonoid ...

Journal: :Proceedings of the National Academy of Sciences of the United States of America 2009
Kathryn R Coser Ben S Wittner Noël F Rosenthal Sabrina C Collins Antonia Melas Shannon L Smith Crystal J Mahoney Keiko Shioda Kurt J Isselbacher Sridhar Ramaswamy Toshi Shioda

Emergence of antiestrogen-resistant cells in MCF-7 cells during suppression of estrogen signaling is a widely accepted model of acquired breast cancer resistance to endocrine therapy. To obtain insight into the genomic basis of endocrine therapy resistance, we characterized MCF-7 monoclonal sublines that survived 21-day exposure to tamoxifen (T-series sublines) or fulvestrant (F-series sublines...

2012
Fiona Simpkins Pedro Hevia-Paez Jun Sun Wendy Ullmer Candace A. Gilbert Thiago da Silva Ali Pedram Ellis R. Levin Isildinha M. Reis Brian Rabinovich Diana Azzam Xiang-Xi Xu Tan A. Ince Ji-Yeon Yang Roel G.W. Verhaak Yiling Lu Gordon B. Mills Joyce M. Slingerland

Purpose: More effective, less toxic treatments for recurrent ovarian cancer are needed. Although more than 60% of ovarian cancers express the estrogen receptor (ER), ER-targeted drugs have been disappointing due to drug resistance. In other estrogen-sensitive cancers, estrogen activates Src to phosphorylate p27 promoting its degradation and increasing cell-cycle progression. Because Src is acti...

2017
Jill M. Siegfried Mariya Farooqui Natalie J. Rothenberger Sanja Dacic Laura P. Stabile

The estrogen receptor (ER) promotes non-small cell lung cancer (NSCLC) proliferation. Since fibroblast growth factors (FGFs) are known regulators of stem cell markers in ER positive breast cancer, we investigated whether a link between the ER, FGFs, and stem cell markers exists in NSCLC. In lung preneoplasias and adenomas of tobacco carcinogen exposed mice, the anti-estrogen fulvestrant and/or ...

Journal: :British Journal of Cancer 2004

Journal: :Nature Reviews Clinical Oncology 2019

Journal: :Cancer discovery 2017
Weiyi Toy Hazel Weir Pedram Razavi Mandy Lawson Anne U Goeppert Anne Marie Mazzola Aaron Smith Joanne Wilson Christopher Morrow Wai Lin Wong Elisa De Stanchina Kathryn E Carlson Teresa S Martin Sharmeen Uddin Zhiqiang Li Sean Fanning John A Katzenellenbogen Geoffrey Greene José Baselga Sarat Chandarlapaty

Recent studies have identified somatic ESR1 mutations in patients with metastatic breast cancer and found some of them to promote estrogen-independent activation of the receptor. The degree to which all recurrent mutants can drive estrogen-independent activities and reduced sensitivity to ER antagonists like fulvestrant is not established. In this report, we characterize the spectrum of ESR1 mu...

Journal: :Macromolecules 2022

Polymeric micelles have been extensively used as nanocarriers for the delivery of chemotherapeutic agents, aiming to improve their efficacy in cancer treatment. However, poor loading capacity, premature drug release, non-uniformity, and reproducibility still remain major challenges. To create a stable polymeric micelle with high loading, telodendrimer was developed nanocarrier fulvestrant, an e...

2007
Anthony Howell

Endocrine therapy plays an important role in the management of all stages of breast cancer, and the development of effective endocrine therapies has focused on modifying the response of hormone-sensitive tumors to estrogen. The most widely used agents are the nonsteroidal antiestrogens or selective estrogen receptor (ER) modulators, the class to which tamoxifen, the standard in terms of antiest...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید